

QUARTERLY REPORT

Fiscal Year – 2014

INFORMATION AND DISCLOSURE STATEMENT

Period Ending June 30, 2014



Medical Technologies

d/b/a

RIGHTSMILE, INC.

RIGHTSMILE, INC.
Company Information and Disclosure Statement
For the Period Ending June 30, 2014

Item I: Name of the Issuer and its Predecessor(s):

From August, 2009 to Present:	Rightsmile, Inc.
From June 2007 to August 2009	Potential Holdings, Inc.
From June 2007 to July 2007	Axiom Management, Inc.
From May 2003 to June 2007	Green Power Energy Holdings Corp.
From Incorporation to May 2003	Dr. Owl Online, Inc.

Item II: The Address of the Issuer's Principal Executive Offices:

Company Headquarters:

11601 Wilshire Boulevard, Suite 500
Los Angeles, CA 90025
Tel. (855) 723-3283
www.BGMedTech.com
admin@bdmedtech.com

Investor Relations Contact:

None.

Item III: Security Information

Trading Symbol:	RIGH
Exact Title and Class of Securities Outs.:	Common Stock
CUSIP:	76657X 10 3
Total Shares Auth. As of June 30, 2014	30,000,000,000
Total Shares Issued as of June 30, 2014	29,999,999,468
Total Shares Outstanding as of June 30, 2014	29,999,999,468

Additional Class of Securities:

Trading Symbol:	None.
Exact Title and Class of Securities Outstanding:	Series A Preferred Stock.
CUSIP:	None.
Total Shares Auth. As of June 30, 2014	5,000,000
Total Shares Issued as of June 30, 2014	3,565,000
Total Shares Outstanding as of June 30, 2014	3,565,000

Transfer Agent:

Standard Registrar & Transfer
12525 South 1840 East
Draper, UT 84020
Tel. 801.571.8844 Fax. 801.571.2551

List Any Restrictions on the Transfer of Security: None. Securities subject to applicable restrictions as provided in the Securities Act of 1933, and the rules promulgated thereunder, as amended.

Described any Trading Suspension Orders Issued by the SEC in the past 12 months: None.

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off or reorganization either currently anticipated or that occurred within the past 12 months: On September 20, 2013, the Issuer was re-domiciled in the State of Wyoming, such transaction constitutes an "Type F" reorganization under the Internal Revenue Code.

Item IV: Issuance History:

On or about February 24, 2014, the Issuer sold a ten (10%) percent convertible promissory note to Adamas Fund, LP in the principal amount of \$15,000. (the "Note"). The Note matures August 23, 2014.

Item V: Financial Statements.

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

Rightsmile, Inc.
Balance Sheet

<u>Assets</u>	June 30, 2014 (Unaudited)	December 31, 2013 (Unaudited)
Current Assets		
Cash and cash equivalents	\$230	\$36,247
Accounts receivable	310,960	226,659
Inventory	3,985	4,134
Contingent assets	80,000	80,000
Total Current Assets	395,175	347,040
Fixed Assets		
Fixed assets	324,859	341,519
Intangible assets	530,768	550,796
Total Fixed Assets	855,627	892,315
Total Assets	\$1,250,802	\$1,239,355
<u>Liabilities and Stockholders' Equity</u>		
Current Liabilities:		
Notes payable	\$46,900	\$31,900
Accrued interest	12,835	8,613
Unpaid wages	69,554	40,685
Total Liabilities	129,289	81,198
Stockholders' Equity:		
Preferred stock, \$.001 par value; 5,000,000 shares authorized, 3,565,000 shares issued and outstanding	3,565	3,565
Common stock, \$.00001 par value; 30,000,000,000 shares authorized; 29,999,999,468 shares issued and outstanding	300,000	300,000
Additional paid in capital	4,463,689	4,463,689
Common stock deliverable	(2,164)	(2,164)
Treasury stock	(1)	(1)
Accumulated deficit	(3,643,576)	(3,606,932)
Total stockholders' equity	1,121,513	1,158,157
Total Liabilities and Stockholders' Equity	\$1,250,802	\$1,239,355

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rightsmile, Inc.
Statement of Operations

	For the three months ended		For the six months ended	
	June 30, 2014	June 30, 2013	June 30, 2014	June 30, 2013
Revenue	\$12,200	\$6,000	\$22,299	\$9,000
Cost of Sales				
Lab expenses	485	51	746	549
Freight and delivery	325	313	777	568
Total costs of sales	810	364	1,523	1,117
Gross Profit	11,390	5,636	20,776	7,883
Operating expenses:				
General and administrative	10,374	4,758	19,062	18,219
Sales and marketing	1,007	1,181	1,670	2,021
Depreciation	18,344	24,254	36,688	48,507
Total operating expenses	29,725	30,193	57,420	68,747
Net Loss	\$(18,335)	\$(24,557)	\$(36,644)	\$(60,864)
Net loss per share – basic and diluted	\$(0.00)	\$(0.00)	\$(0.00)	\$(0.00)
Weighted average common shares – basic and diluted	29,999,999,468	29,999,999,468	29,999,999,468	29,999,999,468

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

Rightsmile, Inc.
Statement of Cash Flows

	June 30, 2014	December 31, 2013
Cash Flows from Operating Activities		
Net loss	\$(36,644)	\$(98,180)
Depreciation and amortization	36,688	97,014
	-	-
Changes in operating assets and liabilities:		
Accounts receivable	(84,301)	-
Inventory	149	-
Accrued liabilities	33,091	-
Net cash used in operating activities	(51,017)	(1,166)
Cash Flows from Financing Activities		
Proceeds from notes payable	15,000	-
Net cash received from financing activities	15,000	-
Net increase in cash and cash equivalents	(36,017)	(1,166)
Cash and Cash Equivalents, beginning of period	36,247	37,413
Cash and Cash Equivalents, end of period	\$230	\$36,247

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

RightSmile, Inc.

Notes to Financial Statements for the Period Ending June 30, 2014

Note 1. Organization, History and Business

RightSmile, Inc., (“the Company”) was incorporated in Texas in February, 2001. The Company was redomiciled in the State of Wyoming on September 20, 2013.

RightSmile, Inc. completed a reverse merger with BG Medical Technologies, Inc., on January 18, 2012. The Company intends to formally change its name from RightSmile, Inc., to BG Medical Technologies, Inc., and its ticker symbol with FINRA. RightSmile, Inc. is referred to herein as either the “Company” or, in discussing operations subsequent to January 18, 2012, “BG Medical”. RightSmile acquired BG Medical Technologies, Inc., replacing executive management, and transitioned its core business model to software and technology development specific to medical marijuana, and the complimentary and alternative medicine industry.

Note 2. Summary of Significant Accounting Policies

Revenue Recognition

Revenue is derived from sales of products to distributors and consumers. Revenue is recognized in accordance with Staff Accounting Bulletin (“SAB”) No. 101, “Revenue Recognition in Financial Statements,” as revised by SAB No. 104. As such, the Company recognizes revenue when persuasive evidence of an arrangement exists, title transfer has occurred, the price is fixed or readily determinable, and collectability is probable. Sales are recorded net of sales discounts and terms are recorded by contract.

Accounts receivable is reported at the customers’ outstanding balances, less any allowance for doubtful accounts. Interest is not accrued on overdue accounts receivable.

Allowance for Doubtful Accounts

An allowance for doubtful accounts on accounts receivable is charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and information collected from individual customers. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired.

Stock Based Compensation

When applicable, the Company will account for stock-based payments to employees in accordance with ASC 718, “Stock Compensation” (“ASC 718”). Stock-based payments to employees include grants of stock, grants of stock options and issuance of warrants that are recognized in the consolidated statement of operations based on their fair values at the date of grant.

The Company accounts for stock-based payments to non-employees in accordance with ASC 505-50, “Equity-Based Payments to Non-Employees.” Stock-based payments to non-employees include grants of stock, grants of stock options and issuances of warrants that are recognized in the consolidated statement of operations based on the value of the vested portion of the award over the requisite service period as measured at its then-current fair value as of each financial reporting date.

The Company calculates the fair value of option grants and warrant issuances utilizing the Binomial pricing model. The amount of stock-based compensation recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. ASC 718 requires forfeitures to be estimated at the time stock options are granted and warrants are issued to employees and nonemployees, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates. The term “forfeitures” is distinct from “cancellations” or “expirations” and represents only the unvested portion of the surrendered stock option or warrant. The Company estimates forfeiture rates for all unvested awards when calculating the expense for the period. In estimating the forfeiture rate, the Company monitors both stock option and warrant exercises as well as employee termination patterns. The resulting stock-based compensation expense for both employee and non-employee awards is generally recognized on a straight-line basis over the period in which the Company expects to receive the benefit, which is generally the vesting period.

During the period ending June 30, 2014, the Company did not recognize any stock-based compensation. No options have been granted to date.

Loss per Share

The Company reports earnings (loss) per share in accordance with ASC Topic 260-10, "Earnings per Share." Basic earnings (loss) per share is computed by dividing income (loss) available to common shareholders by the weighted average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings (loss) per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. Diluted earnings (loss) per share has not been presented since there are no dilutive securities.

Cash and Cash Equivalents

For purpose of the statements of cash flows, the Company considers cash and cash equivalents to include all stable, highly liquid investments with maturities of three months or less.

Concentration of Credit Risk

The Company primarily transacts its business with one financial institution. The amount on deposit in that one institution may from time to time exceed the federally-insured limit.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the 10 reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Business segments

ASC 280, "Segment Reporting" requires use of the "management approach" model for segment reporting. The management approach model is based on the way a company's management organizes segments within the company for making operating decisions and assessing performance. The Company determined it has one operating segment as of December 31, 2013

Income Taxes

The Company accounts for its income taxes under the provisions of ASC Topic 740, "Income Taxes." The method of accounting for income taxes under ASC 740 is an asset and liability method. The asset and liability method requires the recognition of deferred tax liabilities and assets for the expected future tax consequences of temporary differences between tax bases and financial reporting bases of other assets and liabilities.

Recent Accounting Pronouncements

The Company continually assesses any new accounting pronouncements to determine their applicability to the Company. Where it is determined that a new accounting pronouncement affects the Company's financial reporting, the Company undertakes a study to determine the consequence of the change to its financial statements and assures that there are proper controls in place to ascertain that the Company's financials properly reflect the change. The Company currently does not have any recent accounting pronouncements that they are studying and feel may be applicable.

Note 3. Description Of Business

Plan of Operation

In February 2011, RightSmile acquired Kazore, Inc. dba Full Spectrum Media (now DevTek, LLC), changing its core business from teeth whitening systems to online marketing and development, including web, mobile application, and search engine optimization. In January 2012, RightSmile acquired BG Medical Technologies, Inc., replacing executive management, and began the transition of its core business model to software and technology development specific to medical marijuana, and the complimentary and alternative medicine industry. In 2013, the Company wound down DevTek, LLC, liquidating DevTek assets to cover outstanding debts and liabilities specific to DevTek, LLC. BG Medical maintains in-house labor to fulfill all previous DevTek related contributions, including contractual online marketing and development, including web, mobile application, and search engine optimization.

BG Medical develops Internet technology and biotechnology, focusing on medical cannabis, cannabis commerce, and natural health care solutions. Its products collect data through a network of proprietary software, utilized by patients, retail operators, and medical professionals. The Company's current flagship product, BudGenius.com, is a social web platform designed to assist cannabis patients in selecting regionally available medicine paired to their needs. The Company operates an analytical chemistry laboratory designed for natural medicine study, which is utilized to determine potency and safety guidance for patients and medicine manufacturers. Data collected from the laboratory is combined with patient feedback to produce information that benefits retail operators and informs

patients on best available treatment options. BudGenius.com maintains the most comprehensive online public database for scientifically tested cannabis worldwide.

In 2010, BG Medical's BudGenius product entered the alternative healthcare market, becoming the nation's most popular medical cannabis testing laboratory. BudGenius' laboratory utilizes gas chromatography machines to conduct its testing procedures. This is similar to methods employed by pharmaceutical laboratories and biotech research firms. BudGenius results are displayed online upon BudGenius.com and within deployable website tools provided to clients. Results are also shown inside cannabis dispensaries throughout California. BudGenius utilizes custom software to pair specific plant genetics to patient ailments such as pain relief, anxiety, and nausea. Assuming financial resources are in place to do so, BudGenius plans to expand services to also address critical ailments such as cancer, Parkinson's Disease, Alzheimer's, and more.

BudGenius' custom analysis software is the primary differentiator between itself and competitive testing laboratories. BudGenius combines analytical chemistry research with social web software that receives patient feedback (crowd sourcing) to determine the net medical effects of chemicals present within plant medicines. The BudGenius software engine reaches its conclusions by evaluating preprogrammed *quantitative* scientific trial data from (i) published studies in scientific journals and articles listing (ii) exact quantities consumed and (iii) researcher-observed effects; and then combining these calculations with *qualitative data* from (iv) crowd sourced patient feedback from websitesubmitted reviews, listing (v) relative quantity consumed and (vi) self-observed effects. The software engine "intelligence" is increased as additional data is added in real-time.

A variety of natural medicine treatment programs continue to gain popularity globally. Additionally, one third of the U.S. population resides in a region with favorable medical cannabis laws. However, in recognition of cannabis legal ambiguities, BG Medical's product strategy is strictly focused on data collection, data analysis, and data display. BG Medical does not sell, grow, harvest, cultivate, or distribute medical cannabis.

On occasion BG Medical also provides technical marketing services to third party clients, including design consultation, social Internet advisement, software engineering, and campaign management for web and mobile audiences.

BG Medical Technologies is focused on building medical treatment infrastructures that combine interactive desktop and mobile applications to provide an affordable alternative to rising healthcare cost concerns.

Management does not believe that cash from operations will be sufficient to meet its cash obligations, and it will be required to raise additional capital through private securities offerings to fund its research, development, and the planned expansion of its operations. In late 2013, BG Medical entered into an agreement with a reputable private equity firm to provide capital financing, although there can be no assurance that BG Medical will be able to raise the required capital to complete its goals in full.

Results of Operations

BG Medical applies two primary technology strategies, each centered on Internet-based healthcare services, data collection, and data analysis. The first strategy focuses on technologies related specific to state-approved medical cannabis treatment programs, while the other focuses on technologies related to naturopathic healthcare and complimentary alternative medicine. BG Medical has formed its mission directives around the belief that marijuana as a medical application is an evolving world viewpoint that is introducing mainstream consumers to the intersection of advanced plant-based treatments with socially-driven Internet technology.

In Q4 2012, the Company completed debt obligations that had been negotiated in the previous quarter. Upon completion, BG Medical reevaluated the relationship the company previously held with Baron Capital Enterprises (BCAP), a debt holder in the Company, and consultant to debt holders associated with the Company prior to the January 2012 reverse merger with BG Medical. Executive management concluded that financing commitments previously set forth by BCAP to BG Medical had not met expectations. As a result of an internal study examining historical transactions, management further alleged that ongoing actions by BCAP could cause irreparable harm to both Company and shareholders. To protect shareholder interests and future business interests, the Company sought to limit uncontrolled free trading shares from entering the marketplace from methodologies that that did not support business growth and/or shareholder earnings. Stopgap measures were put into place that limited corporate communications until a long-term strategy with sufficient resources had been established. The resultant lack of capital financing as previously planned, coupled with the presence of an unresolved capital financing relationship, created challenges for BG Medical in adhering to stated growth projections that were dependent upon capital support. Furthermore, medical cannabis policy changes in San Diego, CA and Long Beach, CA forced closure of key BudGenius.com clients and prospective clients. These unexpected closures reduced Company profits due to significant resources that had been invested into expanding client relationships within these regions. Evolving municipal policy changes represent operational risks inherent to the medical cannabis industry, and when viewed as a whole, illustrate the consistent ebb and flow for this emerging market.

Throughout 2013, the Company placed its focus on resolving market volatility allegedly resultant from a former financing relationship with Baron Capital Enterprises (BCAP) and its principals, an entity and individual(s) closely involved in providing past financing to

the public entity prior to the 2012 reverse merger, and to a lesser degree, minor financing during the Q1 2012 and Q2 2012 post reverse merger period. BG Medical has no plans to enter into further debt arrangements with previous promissory note holders. The company wishes to distance itself from BCAP and remains committed to preserving shareholder value. Due to the disruptive nature of unwinding the aforementioned relationship(s), the undertaking of preserving the Company's future as an attractive investment prospect eclipsed daily operations and affected previously scheduled technology development. With limited capital resources available, guarding the long-term growth potential of the Company led to a reduction in near-term revenues. These actions forced the introduction of leaner operation models that serve today as a valuable and efficient blueprint for the company as it enters 2014, its fourth year in operation.

In Q2 2013, the Company closely aligned itself and contributed significant labor resources to passing newly proposed Los Angeles city legislation, which if passed, would have introduced mandatory medical marijuana laboratory testing practices for all cannabis dispensaries (retail outlets) within city borders. The Company supported the proposition for the changes it would have introduced to the limited regulatory environment of Los Angeles. In addition to mandating analytical testing for all cannabis products, the proposition also included operational guidance for dispensaries, consumer protections, and neighboring resident protections. Unfortunately, an opposing bill was passed that did not impose testing regulations and further reduced the number of dispensaries allowed to conduct business within Los Angeles. This affected BudGenius market growth in the Los Angeles region was subsequently affected by the closure of several clients as per the passed proposition. However, the subsequent limited enforcement of certain measures within the bill has created an ongoing topic of public debate in regards to its effectiveness. BG Medical expects future legislation to address these issues, including the addition mandates for testing. In relation to ongoing trends, mandatory testing throughout all states and municipalities is expected as the cannabis industry continues to mature. BG Medical and BudGenius currently serves several Los Angeles businesses, that despite the lack of current legislative decree, willfully choose to conduct laboratory testing for the benefit of their patients. BG Medical continues to support and contribute to legislation throughout the nation that proposes cannabis testing as a necessary component for patient safety and consumer knowledge.

As of Q4 2013, BG Medical successfully entered into capital agreements with a reputable finance firm to accelerate its proprietary technology development and to strengthen a market evaluation based on the Company's future earning potential. BG Medical continues to seek accredited investors and respectable financial relationships to fulfill Company capital needs and growth development through its planned expansion. The successful implementation and launch of recreational marijuana legislation in Colorado has led to significantly enhanced interest from mature investment firms seeking to capitalize on industry growth opportunities. As a seasoned company within the marijuana industry, BG Medical is well positioned to engage these opportunities.

BG Medical's medical cannabis platform, BudGenius.com, operates in both the largest state-approved population for medical cannabis dispensaries nationwide and the most densely populated local region, California and the Los Angeles metropolitan area, respectively. BudGenius has developed the most highly visited web portal for a cannabis laboratory. Up to 12,000 patients per day research their medicine on BudGenius.com. BudGenius has also created what BG Medical believes to be the largest online database of high-definition microscopic photographs of cannabis strains in the world.

BG Medical expects ongoing and accelerating growth in state-approved medical cannabis patient communities nationwide. However, sales revenue in the cannabis market segment is dependent on market trends. Volatility in mature medical cannabis markets such as California, Colorado, and Washington are expected through the ongoing clarification of state and federal positions regarding medical cannabis distribution. Cautious growth rates are expected in emerging markets in Arizona, Illinois, Michigan, Nevada, Oregon, and Washington DC, as well as latent markets in Alaska, Connecticut, Delaware, Hawaii, Maine, Maryland, Massachusetts, Montana, Nevada, New Hampshire, New Jersey, New Mexico, Rhode Island, and Vermont. BG Medical believes new market growth rates will increase significantly as mature markets set non-volatile standards for emergent markets to emulate. Further market changes are expected as a result of the 2016 United States elections. The Company expects recreational legalization to occur within California, and expects to be politically active in these agendas as it has been with previous legislative efforts. Marijuana industry growth is likely to be further propelled by the results of pending favorable cannabis legislation introduced in Florida, Kansas, Minnesota, Missouri, New York, Ohio, Pennsylvania, and South Carolina, and future state legislative efforts. Consolidation in the quantity of regional cannabis dispensaries is occurring in mature markets, leading to an expected decrease in revenue potential for products and services based on dispensary density (such as advertising and location portals), in addition to an expected increase in revenue potential for products and services based on recurring patient services, education, and medicine safety (such as the BudGenius product platform). BG Medical expects these trends to continue in a similar manner to many market lifecycles in which newly implemented technologies lower long-term operational costs, and create a price-competitive marketplace that becomes reliant on the efficiency of underlying technology platforms.

Upon facilitation of capital financing agreements erected in Q4 2013, new products and services for consumers and businesses are expected to resume development for enhancing the BudGenius software and data collection platform, including but not limited to, mobile app development, online transparency for laboratory workflow, marijuana genetics and strain mapping, marijuana heritage profiles to highlight sustained and exceptional farmer pedigree, business intelligence data gathering tools, consumer purchase pattern analysis, medical efficacy analysis, loyalty programs, portable diagnostic hardware for patients, and internal tools to optimize company workflow for the purpose of reducing cost of goods sold. A modified release schedule has not yet been determined.

Note 4. Related Party Transactions

None.

Note 5. Stockholders' Equity

Common Stock

The holders of the Company's common stock are entitled to one vote per share of common stock held.

As of June 30, 2014 the Company had 29,999,999,468 shares issued and outstanding.

Preferred Stock

As of June 30, 2014 the Company had 3,565,000 shares issued and outstanding.

Note 6. Commitments and Contingencies

Commitments:

The Company currently has no long term commitments as of our balance sheet date.

Contingencies:

In 2009 through 2011 the Company entered into a series of promissory notes with Baron Capital Enterprise, Inc. The Company disputes the validity of the alleged obligations and claims damages against Baron Capital Enterprise, Inc. for, among other matters, material breach of contract. The Company's balance sheet reflects both the Company's contingent claim as well as an allowance for the disputed obligation.

Note 7. Net Income (Loss) Per Share

For the period ending June 30, 2014, the shareholders of the Company has registered a cumulative net loss per common share of \$.00008

Note 8. Notes Payable

The Company has a series of promissory notes in the aggregate principal amount of \$31,900 bearing interest at a rate of eighteen (18%) percent currently outstanding.

On or about February 24, 2014, the Issuer sold a ten (10%) percent convertible promissory note to Adamas Fund, LP in the principal amount of \$15,000. (the "Note"). The Note matures August 23, 2014.

Note 9. Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. Currently, the Company has limited operating history and has incurred operating losses, and as of December 31, 2013 the Company had an accumulated deficit of \$3,643,576. These factors raise substantial doubt about the Company's ability to continue as a going concern. Management believes that the Company's capital requirements will depend on many factors including the success of the Company's development efforts and its efforts to raise capital. Management also believes the Company needs to raise additional capital for working capital purposes. There is no assurance that such financing will be available in the future. The conditions described above raise substantial doubt about our ability to continue as a going concern. The financial statements of the Company do not include any adjustments relating to the recoverability and classification of recorded assets, or the amounts and classifications of liabilities that might be necessary should the Company be unable to continue as a going concern.

Note 11. Subsequent Events

None.

Item VI: Description of the Issuer's Business, Products and Services

Description of the Issuer's Business Operations

Rightsmile, Inc. d/b/a BG Medical Technologies, Inc. develops socially relevant technology systems and media content for the medical cannabis and alternative health industry that are the result of extensive analysis of scientific data collected through a proprietary network of software solutions, patients, and medical professionals.

The company's flagship product, BudGenius.com, launched in 2010 and is an informative website for medical cannabis patients, as well as a consumer safety service for dispensaries. BudGenius combines a medical cannabis testing laboratory with social Internet tools to help predict the therapeutic effects of thousands of marijuana strains by combining scientific data and crowd-sourced reviews. The platform is designed to assist patients in selecting cannabis medicine paired to their specific needs. BudGenius is recognized worldwide as a comprehensive online database for scientifically tested cannabis.

BG Medical Technologies operates its laboratory and executive center in Los Angeles, California. and its technology development centers in Los Angeles, California, and Ukraine.

Date and State of Incorporation

The Issuer was organized under the laws of the State of Texas in February 2001.

The Issuer was re-domiciled under the laws of the State of Delaware on March 28, 2003.

The Issuer was re-domiciled under the laws of the State of Nevada on September 14, 2006.

The Issuer was re-domiciled under the laws of the State of Wyoming on September 20, 2013.

The Issuer's Primary and Secondary SIC Code

Primary – 8700, Engineering, Research, Management

Secondary – 8999, Services not elsewhere classified

Principal Products or Services, and Their Markets

The Issuer offers medical cannabis testing and analysis for use by medical cannabis patients.

Item VII: Describe the Issuer's Facilities

The Issuer leases its facilities at no cost pursuant to an unwritten agreement with the primary lessee of the premises.

Item VII: Officers, Directors and Control Persons

Names of Officers, Directors and Control Persons:

<u>Name</u>	<u>Position</u>	<u>Business Address</u>
Angel Stanz	Chief Executive Office	111601 Wilshire Blvd, #500, Los Angeles CA
Salvatore Tuzzolino	Control Shareholder	8502 E. Chapman Avenue, Orange CA

Legal/Disciplinary History:

(a) A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

N/A

(b) The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

N/A

(c) A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

N/A

(d) The entry of an order by a self-regulatory organization that permanently or temporarily barred suspended or otherwise limited such person's involvement in any type of business or securities activities.

N/A

Beneficial Owners:

<u>Name</u>	<u>Position</u>	<u>Securities Owned</u>
Angel Stanz	Chief Executive Office	3,500,000 shares Series A Preferred
Salvatore Tuzzolino	Control Shareholder	26,655,792,728 shares common stock

Item IX: Service Providers.**Legal Counsel**

Adam S. Tracy
Securities Compliance Group, Ltd.
9107 Wilshire Blvd., Suite 450
Beverly Hills, CA 90210
Tel. (888) 978.9901
at@ibankattorneys.com

Accountant or Auditor

N/A

Investor Relations Contact

N/A

Other Advisor

N/A

ITEM X: Issuer Certification.

I, Aaron Stanz hereby certify that:

1. I have reviewed this Quarterly Report for the Period Ending June 30, 2014 of Rightsmile, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

Dated: August 20, 2014

By: /s/ Aaron Stanz

Its: Chief Executive Officer